Compare BridgeBio Pharma Inc (BBIO) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs VanEck Vietnam ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while VanEck Vietnam ETF trades at $17.77. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, VanEck Vietnam ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | VNM | |
|---|---|---|
Market Cap | $16.61B | — |
Sector | Health | Sector/Thematic |
52-Week High | $90.17 | $19.80 |
52-Week Low | $47.29 | $16.34 |
Enterprise Value | $18.16B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
VNM trades at $17.44, showing minimal daily change. Technical indicators are bullish overall, with moving averages signaling strength, while oscillators remain neutral. Key support and resistance levels are tightly clustered around $17 and $18. Recent news highlights regional capital flows and Vietnam-specific challenges, including power grid strain and FTSE Russell's emerging market reclassification affecting the ETF's performance.
The outlook is mixed, with technical strength countered by fundamental data gaps and external risks. Investment opportunity hinges on Vietnam's economic trajectory and foreign investment inflows, but risks include macroeconomic pressures and domestic infrastructure issues. Clarity on financial metrics is essential for a complete assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
